---
layout: default
title: Reslizumab
parent: Model Prediction Only (L5)
nav_order: 795
evidence_level: L5
indication_count: 2
---

# Reslizumab
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **2** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Reslizumab: From Eosinophil-Targeted Therapy to Immune Thrombocytopenia

## One-Sentence Summary

Reslizumab is an anti-IL-5 monoclonal antibody that depletes eosinophils. It is marketed in Canada as CINQAIR, but the original approved indication is not recorded in the data supplied.
The TxGNN model predicts it may be effective for **thrombocytopenia due to immune destruction**,
but there are currently **0 clinical trials** and **0 publications** supporting this direction, so this is a model prediction only.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not recorded in the Health Canada license data |
| Predicted New Indication | Thrombocytopenia due to immune destruction |
| TxGNN Prediction Score | 99.53% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 1 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the drug record. Based on the information supplied, reslizumab is an anti-IL-5 antibody that reduces eosinophils. Its efficacy in the original indication cannot be confirmed because no approved indication text is on file.

No established link between IL-5/eosinophil biology and immune-mediated platelet destruction (such as immune thrombocytopenia) is supported by the supplied data. The high TxGNN score (99.53%, rank 8,844) is a knowledge-graph prediction. It may reflect general proximity between immune pathways and should not be read as clinical evidence.

A second prediction, **primary release disorder of platelets** (score 99.25%), has the same limitation. This is a qualitative platelet function defect, and no direct mechanistic link to IL-5 targeting is evident.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available for the predicted indication of immune thrombocytopenia.

For the second prediction (primary release disorder of platelets), one paper is linked, and it does not directly support that indication:

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [20565230](https://pubmed.ncbi.nlm.nih.gov/20565230/) | 2010 | Review | Curr Med Res Opin | Management of hypereosinophilic syndrome, including mepolizumab. It supports anti-IL-5 use in eosinophilic disease but does not address platelet disorders. |

---

## Canada Market Information

| DIN | Product Name |
|---------|------|
| 2456419 | CINQAIR |

---

## Safety Considerations

- **Drug Interactions**: No interaction records were found in the queried data.

Please refer to the package insert for warnings and contraindications.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction rests only on a knowledge-graph score. There are no clinical trials or publications for immune thrombocytopenia, and no mechanistic link is supported by the supplied data. The only literature linked to the second prediction concerns eosinophilic disease, not platelet disorders.

**To proceed, the following is needed:**
- The Health Canada package insert (approved indication, warnings, contraindications). This is a blocking gap for safety screening.
- Detailed mechanism of action data (for example, from DrugBank).
- A literature and trial search for any link between IL-5/eosinophil biology and immune-mediated platelet destruction.
- Clarification of the original approved indication, dosage form and route of administration for CINQAIR.

*This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

